Gajanan N. Sapkal

This study shows that re-infection with Delta and B.1 variants in recovered Syrian hamsters results in reduced disease severity compared to primary infection, while Delta AY.1 causes milder disease and maintains neutralizing antibody responses.

This study evaluates the neutralizing antibody response of different groups against SARS-CoV-2 Delta and its derivatives using PRNT50.

The paper evaluates the neutralizing activity of sera from vaccinated and recovered individuals against SARS-CoV-2 Delta, Delta AY.1, and B.1.617.3 variants, finding reduced but still effective neutralization.

This study compares the pathogenicity and host response of SARS-CoV-2 Delta and B.1.617.3 variants with B.1 in Syrian hamsters, finding increased disease severity and transmission potential for Delta.

Sera from 26 BBV152/COVAXIN recipients neutralised the UK variant about as well as a heterologous strain in plaque reduction tests, arguing against escape from vaccine-induced antibodies.